<DOC>
	<DOCNO>NCT01555294</DOCNO>
	<brief_summary>Multiple risk factor contribute atherosclerosis , ultimately result clinical manifestation cardiovascular disease . Atherosclerosis result functional morphological change vessel wall , measure ultrasonography . The current study design 1 . To evaluate whether non-invasive measurement atherosclerosis independent predictor cardiovascular disease 2. delineate new biochemical parameter genetic variation , allow earlier effective preventive therapy 3 . The investigator intend set guideline use NIMA outpatient set facilitate early detection increase cardiovascular risk monitor life-style pharmaceutical intervention . In general population Familial Combined Hyperlipidemia .</brief_summary>
	<brief_title>Evaluation Non-invasive Measurements Atherosclerosis Cardiovascular Risk Stratification</brief_title>
	<detailed_description>Cardiovascular disease ( CVD ) major cause death develop country . Atherosclerosis main cause CVD . Abundant evidence indicate 4 major independent risk factor atherosclerosis CVD include cigarette smoking , elevate blood pressure , elevate total cholesterol diabetes mellitus . However , major problem clinical medicine every level risk factor exposure , large inter-individual variation amount atherosclerosis development CVD . Therefore , difficult predict CVD risk individual patient base risk factor screen alone . Non-invasive measurement atherosclerosis ( NIMA ) : An indicator overall effect know unknown potential risk factor atherosclerosis vivo assess measure atherosclerosis directly vessel wall . This also provide opportunity measure atherosclerosis develop symptom CVD , change arterial wall precede clinical symptom CVD . Objectives : ( 1 ) The main objective evaluate whether NIMA independent predictor CVD thus add information traditional risk factor stratification . ( 2 ) Furthermore , delineate new biochemical genetic risk factor , allow earlier effective preventive therapy . ( 3 ) We intend set guideline use NIMA outpatient set facilitate early detection increase cardiovascular risk monitor life-style pharmaceutical intervention . We evaluate 4 different NIMA , base ultrasound tonometry technique , include intima medium thickness ( IMT ) , endothelial function flow mediate dilation ( FMD ) , ankle-brachial index ( ABI ) , Pulse Wave Analyses ( PWA ) pulse wave velocity ( PWV ) . The power NIMA , predict cardiovascular event study two available population , low risk population cohort , Nijmegen Biomedical Study ( NBS ) high risk population , family Familial Combined Hyperlipidemia . The NBS prospective population survey aim investigating frequency genetic variation general population . The study population recruit sex- age-stratified random sample inhabitant Nijmegen 20 90 year old ( n=10.000 ) . Recruitment start October 2001 . The present study substudy NBS . A follow-up approach use evaluate whether NIMA related future cardiovascular event . In total 1517 participant age 50-70 year include . FCH common inherit hyperlipidemia man . Affected individual characterize elevate cholesterol and/or triglyceride level associate trait include small-dense LDL , insulin resistance , oxidative stress increase apoB level , propose contribute increase risk CVD . So , population informative evaluate relevance NIMA CVD risk assessment patient exhibit numerous , additive risk factor , miss traditional cardiovascular risk assessment . Our data base contain unique population 40 well-characterized FCH family , include 687 patient , relatives spouse 5 year follow-up data . These family participate ongoing long-term follow-up program registration CVD . All four NIMA 's , include IMT , ABI , PWV/PWA , FMD , traditional new biochemical genetic parameter measure population . The relevance NIMA identify subject increase risk CVD determine . Furthermore , effect risk factor IMT , ABI , PWV FMD study , include clinical traditional risk factor new biochemical parameter genetic variation . Innovative aspect : We develop evidence base protocol NIMA show presence atherosclerosis clinical manifestation CVD improve cardiovascular risk stratification beyond traditional risk factor screen . Furthermore , delineate new risk factor , include biochemical parameter genetic variation , contribute design optimal ( new ) treatment develop new strategy prevention CVD general population high risk population , FCH . Clinical relevance : If NIMA turn provide powerful information identify subject increase risk CVD incorporate NIMA clinical practice guideline purpose cardiovascular risk stratification evaluation risk management strategy . The identification potential new biochemical and/or genetic risk factor helpful design optimal treatment develop new strategy identification prevention CVD general population family FCH .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<criteria>Populationbased cohort : age 5070 year inclusion recent symptomatic CV disease ( &lt; 6 month ) Familial Combined Hyperlipidemia : age &gt; 18 year pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>( subclinical ) atherosclerosis</keyword>
	<keyword>non-invasive measurement</keyword>
	<keyword>intima-media thickness</keyword>
	<keyword>flow-mediated dilation</keyword>
	<keyword>pulse wave velocity analysis</keyword>
	<keyword>fatal non-fatal cardiovascular event</keyword>
	<keyword>ankle-brachial index ( rest exercise )</keyword>
	<keyword>general population</keyword>
	<keyword>Familial Combined Hyperlipidemia</keyword>
</DOC>